Key result
FOXC1 regulates vascular smooth muscle cell activation and quiescence during vascular injury and atherosclerosis.
Answers are grounded in this paper and cite their sources.
FOXC1 is identified as a key transcriptional regulator of smooth muscle cell plasticity in vascular disease, presenting a potential pharmacological target for promoting lesion stability.
Smooth muscle cell-related transcription factors have been associated with coronary artery disease in large genome-wide association studies, increasing their translational value for therapeutic investigations. Our study shows for the first time that FOXC1 is a major transcriptional regulator in vascular injury and atherosclerotic lesions, causally implicated in the disease. Functionally, our data suggest that FOXC1 modulates smooth muscle cell activation vs quiescence by regulating key pathways involved in cell adhesion, cell cycle progression, and actin cytoskeleton organization. Further investigations should focus on elucidating the mechanistic basis of these regulatory effects and assessing whether this axis could be pharmacologically targeted to promote lesion stability.
No takes yet. Share an insight, caveat, or question.
Rykaczewska et al. (2026) studied Vascular injury and atherosclerotic lesions. FOXC1 was evaluated on Smooth muscle cell activation vs quiescence. FOXC1 acts as a major transcriptional regulator in vascular injury and atherosclerotic lesions, modulating smooth muscle cell activation versus quiescence.
Synapse has enriched 10 related papers. Consider them for comparative context: